You are here: Industry Insights > Vir

News List

Gates Foundation supports HIV and malaria research pharmatimes
January 15, 2022
Vir Biotech has launched a new antibody research initiative, expanding its partnership with the Bill & Melinda Gates Foundation to include the advancement of new innovations for HIV and malaria treatment.
GSK and Vir enter supply deal with European Commission for Covid-19 drug pharmaceutical-technology
July 29, 2021
GlaxoSmithKline and Vir Biotechnology have entered a joint procurement agreement with the European Commission (EC) to deliver up to 220,000 doses of the companies’ experimental drug, sotrovimab, to treat Covid-19.
GSK Singapore and Vir Biotechnology Announce Advance Purchase Agreement with the Government of Singapore for Monoclonal Antibody Sotrovimab (VIR-7831) prnasia
June 30, 2021
GlaxoSmithKline Singapore and Vir Biotechnology announced an agreement with the Government of Singapore for the supply of sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of patients with COVID-19 who do not require ...
GSK-Vir’s Covid-19 drug sotrovimab obtains positive EMA opinion pharmaceutical-technology
May 25, 2021
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion for GlaxoSmithKline (GSK) and Vir Biotechnology’s sotrovimab (VIR-7831) as early Covid-19 treatment.
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19 worldpharmanews
April 16, 2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and ...
GSK and Vir seek EUA for monoclonal antibody to treat Covid-19 pharmaceutical-technology
March 30, 2021
GlaxoSmithKline (GSK) and Vir Biotechnology have applied to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) for SARS-CoV-2 monoclonal antibody VIR-7831 (GSK4182136) to treat Covid-19.
Lilly, Vir and GSK report positive data from Covid-19 antibody trial pharmaceutical-technology
March 30, 2021
Eli Lilly and Company, Vir Biotechnology and GlaxoSmithKline (GSK) have reported topline data from the expanded Phase II BLAZE-4 trial of bamlanivimab (LY-CoV555) co-administered with VIR-7831 (GSK4182136) in low-risk adult patients with mild to ...
Vir, GSK to seek EUA for COVID-19 antibody therapy expresspharma
March 12, 2021
Vir and GSK also said that a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, South African and Brazilian variants of the coronavirus.
US closes enrolment in two COVID-19 antibody studies due to futility europeanpharmaceuticalreview
March 08, 2021
The sub-studies evaluating VIR-7831 and BRII-196 with BRII-198 have stopped enrolment based on recommendations from the Data and Safety Monitoring Board.
GSK, Vir expand collaboration for influenza, respiratory virus therapies pharmaceutical-technology
February 18, 2021
GlaxoSmithKline (GSK) has signed a binding agreement with Vir Biotechnology to expand its existing partnership to research and develop novel therapies for influenza and other respiratory viruses.

Previous page 1 2 Next page